preannouncement. in the third line Revenue Thanks, Cassie, with declined quarter for and X% good everyone. year-over-year, our afternoon,
more by to macro primarily we of This customer was continue disruption anticipated and spending, environment. the quarter around we implemented navigate fell our Our from as cautious a results purchases we caused quarter restructuring forward sales than particularly capital this this had expectations. by challenging
strategy, ]. and are see headwinds necessary we customer preserve commercial and continued growth to cautious While also drive our in structure our [ expect expect these changes to to spending
year $XXX a million. At the our We represents fourth of talk through of revenue results quarter prior implies year. and decline shortly. expect the the in range third flat $XXX from full quarter range of our now X% revenue compared the of more this the to updated Adam range, midpoint will guidance million to details
that our revenue been question no initiated challenging. disappointing. a in had We particularly our platforms it across is has significantly of product sales has major There involved pieces our organization. The all XXXX have growth number and of year made moving transitions
a headwinds, dynamics All space to the backdrop continue macro of since introduction environment of Despite this with most and in of we these portfolio. the the current on we're the competitive believe the a MTS. transition to difficult tool path significant across changing
cell of We will have issues our technologies spatial most and which a and products. single portfolio be using the we in envision leading world analyzed
The to pursuing strategies commercial our are: to to order our accelerate use structure in technologies. first, of staff way foster the evolve widespread we're
customers use ubiquitous a we increasingly we accessible so price. believe now to the across our points, Second, structure that drive experiments. our with can samples. of launches, have be product tend range We cost to And create new price a on best tools we all wide of for leader across
and leadership our and over shown have ability extend push frontiers. over to We our technological
technology are in now the cost. we With both and leader these believe new we offerings,
adoption. and drive products, And ease more of capabilities third, new to to software with advance and order use in our enhance workflows
of the to more consistently are drive reach us customers portfolio of these potential our broad we a to the confident opportunity to taking enable across the Finally, to that in democratization I'm large and investment ahead. approach reach tend objectives execute cash technologies diligent we with accomplish management. steps the will full the
up For call long-term confident they our strategies outlook rest set I year. the what and doing and to financials growth. us advance discuss will Adam third our quarter the impacts detail to will why we're rest future of then more our specific for provide of for on the today, the we're will
Let's the commercial to changes organization. start with making we've been our
engage our we sell As earnings customer types customers. research changes call, we segments. last transform our on shared ground how We infrastructure foundational set to diverse of a up And to re-architected from the commercial making our and sales users structure converting we researchers whether academic serve the better new their we more new to designed into adoption customers, team or ecosystem. driving all in distinct our up or settings, top-tier to bringing needs, our biopharma among focus scaling with
accounts, we on and XXx driving this, expansion customers. of the equipment focused better focused organization, to a creating areas creating exclusively the by which accomplish added capital new unique sector adding key is team on specialization generation and and biopharma distinct that new emerging opportunities To placements to serving next dedicated distinct nurture needs team in instrument a a
to addition manageable territory drive our we this specialization, territory more to recalibrated sales make to of In utilization force. sizes a and efficient more also
they the the disruption the where sales areas necessary, disruption Ultimately, than structure changed largest were did anticipated. cause most. in changes more these the we While this is
And of customer For capital equipment a example, have open still over Americas number sales roles. our large in coverage new XX% biopharma of within the teams quarter. accounts the and
more and these our to and There clarity incentives. processes. now confident the our working organization. work focus rigor in with right full I'm fill the realize open potential to creating We're count. improved make teams were have defined head fast targeted more is still them see our and to an of changes do already roles Our commercial to
the getting customers are to new and territories. with executives onboarding still speed and up account Our
our deliver before see our impact approach. across benefit will the efficient new we the full portfolio. and and drive open help expect We new take growth confident customers will changes from the We're to these experience it time best opportunities up us
Turning portfolio. to our Chromium
particular been have launching focus been for lowering direction the products has us. access cell at time, we cost and new single aimed of some step and driving capabilities by another a took elasticity As We ultimately analysis. expanding into communicating recently in this for price
compared for flexible new per with cells and translational assay of highest to now fivefold less to and performing standard GEM-X multisite previous cell cell First, over Flex. the bringing reduction technology most megascale we're enables for of cell screens, our launch products.
We're setting others. per for CRISPR architecture. GEM-X can researchers a millions projects our than Customers run $X.XX new opportunities and Flex studies, cost the for among broader GEM-X avastin
cost to scale, small sample, a Universal we GEM-X even decrease Second, their in Multiplex. per launched
sample. approximately can gene flagship independent capabilities researchers X is and For up cell $XXX to new multiplexing a This universal a brand run per this samples X,XXX GEM-X for product, lease batch customers, even for expression year. comparable March assays, X cost lowering which for to our of in margins Furthermore, gross our we have consumables. products barriers these we're current launched this while
launched affordable point U.S. address single-cell workloads. a researchers instruments, Chromium generate nontenant only CapEx to price we XO analysis. into to as single less X, at to cell routine with serves high-quality areas, a $XX,XXX. costs compared of and labor and list time, experimental X budget-friendly high-performance trade enables Chromium most Finally, a handle data
and GEM-X X. multiplex are X-prime Our the singleplex Universal available on assays
also to our uniquely oplimit customers, suited the translational these With addressing and should is opportunity required with more by to significantly capabilities bottom line plex a research. adoption.
Chromium only ease have samples, open be for software delivered the commercial quantities. of research. of include drive expanding clinical use input, FFP more At example, price. samples new time, we're single single-cell we to launches, which fourfold were for delivered enhance With primary protocols, constrained in cell previously for up and are plex, limited biobank It amounts assay same sell the compatible open that we've cell GEM-X reduction vast a
a multiply eliminates analyze Universal the single sample for need the library to Multiplex, is on-chip introduced [ to is sample prep workload example simplifying the restress which into throughput. efficient samples process ] solutions for multiplexing and run. sample unique compared to greater for fixation On-chip automation multiplexing more upstream hands-on new whole to elegant built the tagging, Another other fixation enable an reducing way GMAC block And upstream expand and sample have workflow, time improve compatibility and in we methods. to
easier we annotation new of we've products, sub and leadership the With workflows go research a is single biggest from cell one differentiation cell critical Cell challenges to deliver often. software we're it our capability, single-cell to problem hard types side, customers. of part studies more Altogether, in for data single strength, analysis. for excited fundamentally this software and addressing analysis Insight. enable and for of faster adopt a methods researchers portfolio we're delivered more experiment more automated to will introduced our the annotation, the of taking about and On new and most
along the to refer Relations to you posted encourage we'll our and materials information, earnings. on website Investor product additional For supplemental we with
single spatial on motivated cell, execute continued usage are by our the were this HD by spatial platforms. to We consumables and Visium continue adoption encouraged we Xenium immense the quarter also with of facade. we potential As of
-- beginning Within to the move the initial starting reorder busily now seeing see majority customers and labs of we're of order we're are evaluation, that Vinzenplatform, good wave trends. the to past see
an new encouraging at of solid busing with this side of start In continues the researchers.
Adoption product the HD, brings of to seeing a we are sign customers system Visium of pace. instrument addition, majority our benefits
CytAssist to standard clear CytAssist that for critical use is over key enabling that complete robust straightforward experience like customers. made Our lines. has delivering and it the workflow, histologists years to for customers a allows an one solution instrument a is
scientific ensuring to preservation integral and by more accurate our for Additionally, is CytAssist and experience. high-quality customers' specialty, consistency, precision data results
platform, leading Xenium the runs. trends growth our their we support their strong growth well sequential broad continue Xenium see use. consumables of and platform consistently with spectrum over quality spatial cases utilization encouraging and on Within we on accommodate ways time. products adoption customers' overall continued the QX, XK a and and revenue customers sequentially, of Xenium research from may these number These questions the on We the ease to in use saw research data complementary very in hear of feedback to of
making forward, requires by look scale high measuring molecules, the understanding and cells underlying we ahead. biology opportunity progress by at immense the As large I'm we're and motivated encouraged IT tissues and resolution.
month's visions work delivering these the came early My Meeting health to their margin studies, and spatial to of days. fueled applications more conviction technologies these the very I for the away disease. Human and doing transform think future. capabilities are customers, today a by both But single and cell to world. Atlas new around from is X projects still our translational by explore the Our energized community's and last plans the are fundamental could complex understanding larger they're General world's high-impact Cell researchers that
some cell my single spatial and life to reinforce continue exciting that the and belief game-changing most these like in Conversations the be sciences. opportunities of
strong researchers,] adoption space see health to translation with cutting continue This research opportunity the genomics across While there larger is including health, immunology, edge different believe or spans an in metabolic basic academic disease weather we in multiple even opportunity across fields, and women's [ many we broader such aging obligations. science and others. oncology, neuroscience, of
because kinds and see opportunities yet campaigns. we routinely cohorts applications, at in embarking translational early cell just customers, well-established that exist customers, moving large or screening massive analyzing know Even running interest whether on not our many of patient for among interest We large-scale scale. experiments, towards new use academic easing or
increasing across spatial the is development single technologies entire cell process. biopharma, continuum interest drug there and to In of apply the
of the and focused or drug In groups drug of identification disease cell are emergence of characterization open as [ of many preclinical on up bottle development single of large-scale progression context and broad reach applying ] CRISPR a mechanism cases, example, in action. use should and experiment combinatorial superior the target tools spatial discovery, range screens. especially For for organized therapy including work, a
ways profiling is which tools enhance trials, applications opportunity drug exists the accelerate believe screening becoming product biomarker support to to therapy in even an to apply We our characterization. of environment only technologies is development discovery many now another space clinical and have cell larger potential and as And possible. translation there exciting our cellular
And deliver its a firmly and to solid had ahead challenges, a certainly while have in and we're with that a vast has opportunity we spatial. company there sizable built foundation is franchise cell this it. on We believe the year single best
call, board. XXx. turn like us and officially to I'll over I'm I have our as excited CFO, announced Adam, that, it over new joining we our welcome turn to to would Before Adam. he last on I'd to him really be him On to it With
